title: Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
abstract: OBJECTIVE
  To investigate the efficacy of bosentan in patients with single-ventricle physiology who were unable to undergo right-sided heart bypass surgery because of high pulmonary vascular resistance and pulmonary artery pressure.
  
  
  METHODS
  Eight patients with single-ventricle physiology (2 male and 6 female; aged 7 months to 5 years, median 1 year) were enrolled. Prior surgical interventions included pulmonary artery banding in 4 patients, Blalock-Taussig shunt operation in 2 patients, and bidirectional Glenn operation in 5 patients. Right-sided heart bypass surgery was contraindicated for all patients because of high pulmonary vascular resistance and pulmonary artery pressure.
  
  
  RESULTS
  Bosentan therapy successfully reduced pulmonary artery pressure and pulmonary vascular resistance in all patients. Mean pulmonary artery pressure at baseline and after bosentan therapy was 21.1 +/- 7.2 mm Hg and 11.9 +/- 4.1 mm Hg, respectively (P < .01). Mean pulmonary vascular resistance index at baseline and after bosentan therapy was 5.7 +/- 3.3 U/m(2) and 1.3 +/- 0.4 U/m(2), respectively (P < .01). Mean pulmonary vascular resistance/systemic vascular resistance at baseline and after bosentan therapy was 0.25 +/- 0.11 and 0.07 +/- 0.03, respectively (P < .01). All patients had improved clinical symptoms and underwent successful Fontan operations.
  
  
  CONCLUSIONS
  Bosentan induces mid-term clinical and hemodynamic improvement in patients with single-ventricle physiology and elevated pulmonary vascular resistance and pulmonary artery pressure. Bosentan therapy may increase the surgical options and improve outcomes in candidates for right-sided heart bypass surgery.
authors.affiliation: Department of Pediatrics, University of Toyama, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Hirono
authors.forename: Naoki
authors.initials: N
authors.lastname: Yoshimura
authors.forename: Masato
authors.initials: M
authors.lastname: Taguchi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Tsuneyuki
authors.initials: T
authors.lastname: Nakamura
authors.forename: Fukiko
authors.initials: F
authors.lastname: Ichida
authors.forename: Toshio
authors.initials: T
authors.lastname: Miyawaki
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D000077300:Bosentan; D002675:Child, Preschool; D005260:Female; D018729:Fontan Procedure; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology / Q000601:surgery; D007223:Infant; D008297:Male; D011651:Pulmonary Artery / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D013449:Sulfonamides; D000077300:Bosentan